CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,047 | +64.9% | 35,217 | 0.0% | 0.01% | +83.3% |
| Q2 2023 | $635 | -18.3% | 35,217 | -27.2% | 0.01% | -25.0% |
| Q1 2023 | $777 | -5.6% | 48,355 | +7.5% | 0.01% | -11.1% |
| Q4 2022 | $823 | -99.9% | 44,989 | 0.0% | 0.01% | -10.0% |
| Q3 2022 | $884,000 | +45.9% | 44,989 | +63.0% | 0.01% | +66.7% |
| Q1 2022 | $606,000 | -22.7% | 27,597 | 0.0% | 0.01% | -14.3% |
| Q4 2021 | $784,000 | +34.9% | 27,597 | 0.0% | 0.01% | +40.0% |
| Q3 2021 | $581,000 | – | 27,597 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |